Legal6 Sept 2024, 12:04 am
Suven Pharmaceuticals' Amalgamation with Casper Pharma Private Limited Listed for Hearing on October 4, 2024
AI Summary
Suven Pharmaceuticals Ltd. has provided an update on the amalgamation of Casper Pharma Private Limited (a wholly owned subsidiary) into and with Suven Pharmaceuticals Limited. The Board of Directors of Suven Pharmaceuticals Limited approved the Scheme of Amalgamation under Sections 230 and 232 of the Companies Act, 2013 and other applicable rules and/or regulations, subject to receipt of applicable regulatory and other approvals. The Hon’ble NCLT has listed the matter for hearing and final disposal of the application on October 4, 2024.
Key Highlights
- Suven Pharmaceuticals Ltd. is amalgamating Casper Pharma Private Limited, its wholly owned subsidiary.
- The amalgamation was approved by the Board of Directors of Suven Pharmaceuticals Limited.
- The Scheme of Amalgamation is under Sections 230 and 232 of the Companies Act, 2013 and other applicable rules and/or regulations.
- The Hon’ble NCLT has listed the matter for hearing and final disposal on October 4, 2024.
- The amalgamation is subject to receipt of applicable regulatory and other approvals.